Genetics

Concluding our 4-part 2022 interview series on cancer, Dr. Achim Regenauer answers questions for Life underwriters on cancer and genetics, questions relating both to cause and to advances in clinical medicine.
 

Greig Woodring, former RGA Chief Executive Officer, joined Paul Carroll, editor-in-chief of Insurance Thought Leadership, in a lively conversation about the ways genomics has the potential to transform life insurance. Contact us to explore what advances in genetics, genomics and medicine can mean for your organization.

Research collaboration between RGA and King’s College London shows potential of genetic predisposition in predicting common diseases
 

This paper is the third iteration of a review first published by RGA in 2016 and revised in 2019. Since that time, the field has progressed so rapidly that a significant update was once again needed.
 

New ‘polygenic’ screening techniques open a Pandora’s Box of ethical issues.
 

Rapid advances in medical science’s understanding of the human genome have led to the recent development of novel gene-based therapeutic strategies. In ReFlections, RGA's Dr. Dan Zimmerman defines gene and cell therapies and provides insights into these rapidly developing and impactful technologies.

RGA Hong Kong and the RGA Asia Pacific regional team explore recent innovations in genetic testing and provide guidance on how insurers can prepare for and adapt to changes on the horizon in the genetic moratorium era.

Applying Modern Biotechnology to Life Insurance Underwriting

Epigenetics can uncover how poor health habits can affect future wellness and is being viewed as a potentially powerful underwriting tool.

Costing hundreds of thousands, even millions of USD per individual, a handful of immuno- and gene therapies have been developed to-date. But in fact it’s no longer correct to talk of just “a handful” – usage expansion is already well underway and set to increase medium term.